Clinical Trial Detail

NCT ID NCT02095054
Title Regorafenib and Cetuximab in Patients With Advanced Malignancy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Cetuximab + Regorafenib

Age Groups: adult senior

No variant requirements are available.